Ablation of Kidney Tumors in Patients with Substantial Kidney Impairment: Current Status

IF 4.7 2区医学 Q1 ONCOLOGY Current Oncology Reports Pub Date : 2024-04-16 DOI:10.1007/s11912-024-01533-6

Toshihiro Iguchi, Yusuke Matsui, Koji Tomita, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Hideo Gobara, Motoo Araki, Takao Hiraki

{"title":"Ablation of Kidney Tumors in Patients with Substantial Kidney Impairment: Current Status","authors":"Toshihiro Iguchi, Yusuke Matsui, Koji Tomita, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Hideo Gobara, Motoo Araki, Takao Hiraki","doi":"10.1007/s11912-024-01533-6","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of review</h3><p>To review the current status of kidney tumor ablation in patients with substantial kidney impairment.</p><h3 data-test=\"abstract-sub-heading\">Recent findings</h3><p>Few reports of kidney tumor ablation in such patients have recently been published. The reported prevalence of patients with stage 4 or 5 chronic kidney disease (CKD) among patients undergoing ablation is 2.0%–10%. In patients with stage 4 or 5 CKD, local tumor control rates were 88%–100%. The effect of ablation on CKD stage is unclear, and the observed deteriorations in kidney function are consistent with both the effect of cryoablation and the natural course of advanced CKD.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>According to guidelines, active surveillance may be selected. The goals of treatment are complete tumor removal and maintenance of kidney function, both of which can be met by ablation. Given the limited treatment options, ablation may play a pivotal role in the management of patients with advanced CKD.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01533-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review

To review the current status of kidney tumor ablation in patients with substantial kidney impairment.

Recent findings

Few reports of kidney tumor ablation in such patients have recently been published. The reported prevalence of patients with stage 4 or 5 chronic kidney disease (CKD) among patients undergoing ablation is 2.0%–10%. In patients with stage 4 or 5 CKD, local tumor control rates were 88%–100%. The effect of ablation on CKD stage is unclear, and the observed deteriorations in kidney function are consistent with both the effect of cryoablation and the natural course of advanced CKD.

Summary

According to guidelines, active surveillance may be selected. The goals of treatment are complete tumor removal and maintenance of kidney function, both of which can be met by ablation. Given the limited treatment options, ablation may play a pivotal role in the management of patients with advanced CKD.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肾功能严重受损患者的肾肿瘤消融术：现状

综述目的综述肾功能严重受损患者肾脏肿瘤消融术的现状。最近的研究结果最近关于此类患者肾脏肿瘤消融术的报道寥寥无几。据报道，在接受消融术的患者中，4 期或 5 期慢性肾脏病（CKD）患者的发病率为 2.0%-10%。在 4 期或 5 期慢性肾脏病患者中，局部肿瘤控制率为 88%-100%。消融对 CKD 分期的影响尚不明确，观察到的肾功能恶化与低温消融的影响和晚期 CKD 的自然病程一致。治疗的目标是彻底切除肿瘤和维持肾功能，而消融术可以实现这两个目标。鉴于治疗方案有限，消融术可能会在晚期 CKD 患者的治疗中发挥关键作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.